Binding of butylated hydroxyanisole to human albumin using a novel dynamic method

2 Final Report on the Safety Assessment of Butylated Hydroxyanisole

Butylated hydroxyanisole (BHA) is used in cosmetic formulations as a chemical preservative and as an antioxidant. Both animal and human studies have shown that BHA is absorbed from the gastrointestinal tract and metabolized. Tissue storage may occur with BHA because of its lipid solubility. However, the amount stored is limited by rapid metabolism and excretion. Reported acute oral LD50 values for BHA in rats varied from 2.0 to > 5.0 g/kg. Formulations containing BHA elicited, at most, minimal or moderate skin and eye irritation in rabbits. An extensive number of subchronic and chronic oral studies have been conducted and are reviewed.

BHA given orally or parenterally to mice and rats was shown to inhibit the carcinogenic effects of a broad range of chemical carcinogens. BHA has been shown to inhibit mutagenesis and was not a mutagenic agent in standard in vitro tests. No evidence of carcinogenicity was observed when BHA was administered to mice by subcutaneous injection, by intraperitoneal injection, or by topical application. No carcinogenesis was demonstrated following dietary administration of BHA to either rats or dogs. An increased incidence of forestomach papillomas and squamous cell carcinomas has been observed in rats fed BHA. Studies with pregnant rabbits, mice, rats, and hamsters receiving BHA during gestation by a variety of oral dosage regimens revealed no significant embryotoxic or teratogenic effects.

Clinical data for BHA in cosmetic formulations indicated that they were generally nonsensitizing, nonphotosensitizing, and only minimally or mildly irritating. It is concluded that BHA is safe as a cosmetic ingredient in the present practices of use.

Comparative pharmacokinetics of butylated hydroxyanisole and butylated hydroxytoluene in rabbits

The widespread use of butylated hydroxyanisole (I) and butylated hydroxytoluene (II) as food antioxidants recently has been criticized by the Food and Drug Administration because of their pharmacological and toxicological effects. Interest also has arisen recently in the use of these compounds as anticancer agents. The purposes of this study were to evaluate the pharmacokinetics of I and II in rabbits and to compare their physicochemical properties with their disposition kinetics. It was found that I has a disposition half-life of approximately 1 hr, compared to 11 days for II. These differences are explained in terms of their lipid solubility and protein binding characteristics.

GLC determination of butylated hydroxyanisole in human plasma and urine

A highly sensitive and specific GLC method was developed for the analysis of butylated hydroxyanisole, a commonly used antioxidant. Concentrations below 100 ng/ml could be detected in human plasma and urine. Preliminary pharmacokinetic studies demonstrated that, upon administration of 100 mg po, butylated hydroxyanisole was quickly absorbed and removed from the plasma with a high degree of intersubject variability.